Large reduction in COGS: By 2025, EnzeneX 2.0 expects to produce 40 kg/1000 L batches at $40/gram, redefining FCCM economics. Lower operational costs and higher productivity can lead to up to 50% ...

Bristol Myers Squibb (BMS) acquired Karuna Therapeutics, the developer of KarXT, in a deal worth US $14.0 billion in equity ...

A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger ...

A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger immune response than a conventional mRNA vaccine for up to one year and at a ...

David Carbone, Director of the James Thoracic Oncology Center and Professor of Internal Medicine at The Ohio State University ...

The FDA has extended its approval of UCB’s BIMZELX to three new indications, extending the use of the drug to a total of four ...

The Swedish biotech company Cellevate has raised €3.2 million in a seed round to fuel the commercialization of its ...

Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with ...

Although vaccines already exist to prevent mpox, high prices and the risk of side effects make it difficult to roll them out ...

With a new investment in its two manufacturing sites in Ireland, Eli Lilly continues implementing the largest expansion ...

The series B fundraising will support the clinical development of next-generation multivalent vaccines against respiratory ...

UCB and Biogen revealed that their Phase 3 study testing dapirolizumab pegol in people with systemic lupus erythematosus met ...